JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
Sasaki, Yusuke; Hamaguchi, Tetsuya; Yamada, Yasuhide; Takahashi, Naoki; Shoji, Hirokazu; Honma, Yoshitaka; Iwasa, Satoru; Okita, Natsuko; Takashima, Atsuo; Kato, Ken; Nagai, Yushi; Taniguchi, Hirokazu; Boku, Narikazu; Ushijima, Toshikazu; Shimada, Yasuhiro;
  PDF(new window)
 Abstract
Background: It is well known that peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is associated with a poor prognosis. However, data on the prognostic significance of modern chemotherapy containing bevacizumab, cetuximab or panitumumab are not available. Materials and Methods: This retrospective review concerned 526 patients with metastatic CRC who were classified into two groups according to the presence or absence of PC, and were treated with systemic chemotherapy, with or without bevacizumab or anti-EGFR antibodies. The genetic background, in particular KRAS, BRAF, and PIK3CA gene mutations, and overall survival (OS) were compared between the two groups. Results: The median OS values were 23.3 and 29.1 months for PC and non-PC patients, respectively (hazard ratio [HR]
 Keywords
BRAF;colorectal cancer;KRAS;peritoneal carcinomatosis;PIK3CA;
 Language
English
 Cited by
 References
1.
De Roock W, Claes B, Bernasconi D, et al (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol, 11, 753-62. crossref(new window)

2.
Douillard JY, Oliner KS, Siena S, et al (2013). Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 369, 1023-34. crossref(new window)

3.
Eklöf V, Wikberg ML, Edin S, et al (2013). The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer, 108, 2153-63. crossref(new window)

4.
Franko J, Shi Q, Goldman CD, et al (2012). Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol, 30, 263-7. crossref(new window)

5.
Garrido-Laguna I, Hong DS, Janku F, et al (2012). KRASness and PIK3CAness in patients with advanced colorectal cancer:outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One, 7, 38033. crossref(new window)

6.
Gonsalves W, Mahoney MR, Sargent DJ, et al (2014). Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst, 106, published online.

7.
Jayne DG, Fook S, Loi C, et al (2002). Peritoneal carcinomatosis from colorectal cancer. Br J Surg, 89, 1545-50. crossref(new window)

8.
Koppe MJ, Boerman OC, Oyen WJ, et al (2006). Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg, 243, 212-22. crossref(new window)

9.
Kraft A, Weindel K, Ochs A, et al (1999). Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 85, 178-87. crossref(new window)

10.
Mao C, Yang ZY, Hu XF, et al (2012). PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol, 23, 1518-25. crossref(new window)

11.
Neumann J, Zeindl-Eberhart E, Kirchner T, et al (2009). Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract, 205, 858-62. crossref(new window)

12.
Pichler M, Balic M, Stadelmeyer E, et al (2009). Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn, 11, 140-7. crossref(new window)

13.
Richman SD, Seymour MT, Chambers P, et al (2009). KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol, 27, 5931-7. crossref(new window)

14.
Sadeghi B, Arvieux C, Glehen O, et al (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer, 88, 358-63. crossref(new window)

15.
Sanger F, Nicklen S, Coulson AR (1977). DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A, 74, 5463-7. crossref(new window)

16.
Tran B, Kopetz S, Tie J, et al (2011). Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer, 117, 4623-32. crossref(new window)

17.
Van Cutsem E, Kohne CH, Lang I, et al (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 29, 2011-9. crossref(new window)

18.
Verwaal VJ, van Ruth S, de Bree E, et al (2003). Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol, 21, 3737-43. crossref(new window)